ECONOMIC-EVALUATION OF HEMATOPOIETIC GROW TH-FACTORS IN THE TREATMENTOF MALIGNANT HEMOPATHIES

Economic evaluation of haematopoietic growth factors in the treatment of malignant haemopathies was undertaken along with clinical trials or retrospectives studies. The cost of the sole treatment was estimated to be 2,302 US$ per cycle. Cost-minimization analyses compared the cos t of a treatment course (chemotherapy, bone marrow transplantation wit h and without haematopoietetic growth factors), and cost-effectiveness analyses estimated the cost per episode of averted febrile neutropeni a. Results appear to be contradictory and do not allow definite conclu sions about the existence of extra costs or of cost savings due to the introduction haematopoietetic growth factors, except in the case of f ilgrastim-mobilized peripheral blood progenitor cell transplantation.